Cargando…

310 Mechanisms of progression of myelodysplastic syndrome to fatal secondary acute myeloid leukemia

OBJECTIVES/GOALS: Aim 1: Define the genetic events that cooperate with Trp53 mutations to mediate the transformation of MDS to sAML at the stem cell level. Aim 2: Use Bayesian networks to model the signaling pathway activation states identify aberrant regulators of self-renewal in LSCs. METHODS/STUD...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Daniel, Noble-Orcutt, Klara, Lue Antony, Marie, Largaespada, David, Myers, Chad, Sachs, Zohar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129666/
http://dx.doi.org/10.1017/cts.2023.363
_version_ 1785030799192489984
author Chang, Daniel
Noble-Orcutt, Klara
Lue Antony, Marie
Largaespada, David
Myers, Chad
Sachs, Zohar
author_facet Chang, Daniel
Noble-Orcutt, Klara
Lue Antony, Marie
Largaespada, David
Myers, Chad
Sachs, Zohar
author_sort Chang, Daniel
collection PubMed
description OBJECTIVES/GOALS: Aim 1: Define the genetic events that cooperate with Trp53 mutations to mediate the transformation of MDS to sAML at the stem cell level. Aim 2: Use Bayesian networks to model the signaling pathway activation states identify aberrant regulators of self-renewal in LSCs. METHODS/STUDY POPULATION: To model the transformation of MDS, I will utilize a mouse model of MDS and sAML. The Trp53 mutated mouse mimics the genetics of human MDS and develops MDS. To discover how additional mutations contribute to disease progression, I use the Sleeping Beauty transposon system which induces random mutations. I propose to use this mouse model to define the molecular mechanisms of transformation of MDS to sAML. I will also measure levels of activated signaling intermediates in sAML using CyTOF. CyTOF is a method of flow cytometry that measures up to 40 proteins simultaneously at single-cell resolution. I will also use Bayesian network to model the signaling architecture of the MDS/sAML stem cells. RESULTS/ANTICIPATED RESULTS: I will identify putative mediators of self-renewal in gene expression data and the corresponding Bayesian networks model. I will prioritize genes and signaling intermediates that act in pathways that rank highly in both methods and those that have previously published roles in self-renewal. Based on prior work, I will focus on EZH2, NFï «B, and mTOR pathways in addition to candidate pathways revealed by these studies. Small molecule inhibitors that target candidate signaling intermediates will be used for experimental validation. I will test the impact of these small molecule inhibitors on LSC self-renewal using serial colony forming assays as well as in vivo mouse reconstitution assays. DISCUSSION/SIGNIFICANCE: We focus on the role of stem cells in the transformation of MDS to sAML. Understanding the mutations and signaling relationships that mediate self-renewal in Trp53 mutant stem cells will allow for precise therapeutic target of this disease and improve outcomes for these patients.
format Online
Article
Text
id pubmed-10129666
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-101296662023-04-26 310 Mechanisms of progression of myelodysplastic syndrome to fatal secondary acute myeloid leukemia Chang, Daniel Noble-Orcutt, Klara Lue Antony, Marie Largaespada, David Myers, Chad Sachs, Zohar J Clin Transl Sci Precision Medicine/Health OBJECTIVES/GOALS: Aim 1: Define the genetic events that cooperate with Trp53 mutations to mediate the transformation of MDS to sAML at the stem cell level. Aim 2: Use Bayesian networks to model the signaling pathway activation states identify aberrant regulators of self-renewal in LSCs. METHODS/STUDY POPULATION: To model the transformation of MDS, I will utilize a mouse model of MDS and sAML. The Trp53 mutated mouse mimics the genetics of human MDS and develops MDS. To discover how additional mutations contribute to disease progression, I use the Sleeping Beauty transposon system which induces random mutations. I propose to use this mouse model to define the molecular mechanisms of transformation of MDS to sAML. I will also measure levels of activated signaling intermediates in sAML using CyTOF. CyTOF is a method of flow cytometry that measures up to 40 proteins simultaneously at single-cell resolution. I will also use Bayesian network to model the signaling architecture of the MDS/sAML stem cells. RESULTS/ANTICIPATED RESULTS: I will identify putative mediators of self-renewal in gene expression data and the corresponding Bayesian networks model. I will prioritize genes and signaling intermediates that act in pathways that rank highly in both methods and those that have previously published roles in self-renewal. Based on prior work, I will focus on EZH2, NFï «B, and mTOR pathways in addition to candidate pathways revealed by these studies. Small molecule inhibitors that target candidate signaling intermediates will be used for experimental validation. I will test the impact of these small molecule inhibitors on LSC self-renewal using serial colony forming assays as well as in vivo mouse reconstitution assays. DISCUSSION/SIGNIFICANCE: We focus on the role of stem cells in the transformation of MDS to sAML. Understanding the mutations and signaling relationships that mediate self-renewal in Trp53 mutant stem cells will allow for precise therapeutic target of this disease and improve outcomes for these patients. Cambridge University Press 2023-04-24 /pmc/articles/PMC10129666/ http://dx.doi.org/10.1017/cts.2023.363 Text en © The Association for Clinical and Translational Science 2023 https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
spellingShingle Precision Medicine/Health
Chang, Daniel
Noble-Orcutt, Klara
Lue Antony, Marie
Largaespada, David
Myers, Chad
Sachs, Zohar
310 Mechanisms of progression of myelodysplastic syndrome to fatal secondary acute myeloid leukemia
title 310 Mechanisms of progression of myelodysplastic syndrome to fatal secondary acute myeloid leukemia
title_full 310 Mechanisms of progression of myelodysplastic syndrome to fatal secondary acute myeloid leukemia
title_fullStr 310 Mechanisms of progression of myelodysplastic syndrome to fatal secondary acute myeloid leukemia
title_full_unstemmed 310 Mechanisms of progression of myelodysplastic syndrome to fatal secondary acute myeloid leukemia
title_short 310 Mechanisms of progression of myelodysplastic syndrome to fatal secondary acute myeloid leukemia
title_sort 310 mechanisms of progression of myelodysplastic syndrome to fatal secondary acute myeloid leukemia
topic Precision Medicine/Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129666/
http://dx.doi.org/10.1017/cts.2023.363
work_keys_str_mv AT changdaniel 310mechanismsofprogressionofmyelodysplasticsyndrometofatalsecondaryacutemyeloidleukemia
AT nobleorcuttklara 310mechanismsofprogressionofmyelodysplasticsyndrometofatalsecondaryacutemyeloidleukemia
AT lueantonymarie 310mechanismsofprogressionofmyelodysplasticsyndrometofatalsecondaryacutemyeloidleukemia
AT largaespadadavid 310mechanismsofprogressionofmyelodysplasticsyndrometofatalsecondaryacutemyeloidleukemia
AT myerschad 310mechanismsofprogressionofmyelodysplasticsyndrometofatalsecondaryacutemyeloidleukemia
AT sachszohar 310mechanismsofprogressionofmyelodysplasticsyndrometofatalsecondaryacutemyeloidleukemia